Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
iShares Russell 2000 Growth Fund
(NY:
IWO
)
337.07
-1.14 (-0.34%)
Official Closing Price
Updated: 8:00 PM EST, Feb 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about iShares Russell 2000 Growth Fund
< Previous
1
2
3
4
Next >
ARDX Stock Is Down Pre-Market After Q4 Earnings Miss, So Why Did This Firm Just Hike Price Target By 80%?
↗
February 20, 2026
Analysts at H.C. Wainwright hiked their price target for Ardelyx shares to $18 from $10.
Via
Stocktwits
Topics
Earnings
Intellectual Property
Invesco QQQ or iShares Russell 2000 Growth ETF: Which is the Better Buy?
↗
February 12, 2026
The Invesco QQQ is one of the most popular ETFs on the market. But is it the best growth-oriented ETF?
Via
The Motley Fool
Topics
ETFs
INMB Stock Rises Pre-Market – What Did The FDA Say About Its Alzheimer’s Trial?
↗
February 12, 2026
Via
Stocktwits
Why Did OUST Stock Catch Retail Attention In Pre-Market Today?
↗
February 09, 2026
The company announced that it completed the acquisition of AI vision specialist StereoLabs SAS earlier this month.
Via
Stocktwits
Topics
Artificial Intelligence
Bakkt Stock Rallies Nearly 20% - What’s Behind The Move?
↗
January 12, 2026
Via
Stocktwits
Planet Labs Stock Gained 7% Today — What Is The Swedish Military Deal About?
↗
January 12, 2026
Via
Stocktwits
Why Did AQST Stock Plunge 40% In Pre-Market Today?
↗
January 09, 2026
Via
Stocktwits
Why Did Kratos Defense Stock Surge 17% Today?
↗
January 08, 2026
Via
Stocktwits
Small-Cap vs. Mega-Cap: Is IWO or MGK the Better Buy Right Now?
↗
February 08, 2026
Explore how sector mix and company size shape the risk and diversification profiles of these two popular growth ETFs.
Via
The Motley Fool
Topics
ETFs
Genius Sports’ Stock Is Down 26% Today – Why Is Retail Wary?
↗
February 05, 2026
Genius Sports said it is acquiring Legend in a transaction valued at up to $1.2 billion, including $900 million payable at closing and an earnout of up to $300 million.
Via
Stocktwits
MDXG Stock Rises As MiMedx Enters Into Exclusive Distribution Agreement For Three Products
↗
February 04, 2026
According to the agreement, Summit Products Group will distribute Hydrelix, NovaForm, and G4Derm Plus, designed to complement MiMedx’s portfolio of leading surgical and wound products.
Via
Stocktwits
Topics
Artificial Intelligence
SOC Stock Declines 10% – What Are The Factors Driving The Selloff?
↗
February 03, 2026
The company disclosed that it has received subpoenas from the U.S. Attorney’s Office for the Southern District of New York and the SEC on reports of selective disclosure of material information to...
Via
Stocktwits
Topics
Government
Law Enforcement
Lawsuit
Why Is SELLAS Life Sciences Stock Falling Today?
↗
October 27, 2025
Via
Stocktwits
Why Did AQST Stock Jump 35% Today?
↗
February 02, 2026
The company received a Complete Response Letter from the U.S. Food and Drug Administration for its New Drug Application seeking approval of Anaphylm, a sublingual film to treat severe Type I allergic...
Via
Stocktwits
Afraid of an AI Crash? These 3 Safer Plays Could Protect Your Portfolio.
↗
January 27, 2026
What if the AI bubble bursts in 2026? Here's how you can invest in a safer way in case AI stocks crash.
Via
The Motley Fool
Topics
Artificial Intelligence
ETFs
IWO vs. VONG: How Does A Small Cap Growth Compare Against A Large Cap Growth Fund
↗
January 26, 2026
These two ETFs cover different Russell Growth Indexes, with different focuses. Here's what they can offer for someone's portfolio.
Via
The Motley Fool
Topics
ETFs
IWO vs. VUG: Comparing Growth ETFs With Different Focuses
↗
January 26, 2026
Explore how IWO’s small-cap diversity and sector mix set it apart from VUG’s concentrated large-cap approach.
Via
The Motley Fool
Topics
ETFs
IWO vs. MGK: How Small-Cap Diversification Compares to Mega-Cap Growth
↗
January 25, 2026
From sector tilts to portfolio concentration, key differences between these ETFs could shape your approach to growth investing.
Via
The Motley Fool
Topics
ETFs
VOOG vs. IWO: Is S&P 500 Stability or Small-Cap Growth Potential the Better Buy Right Now?
↗
January 25, 2026
Expense ratios, sector focus, and portfolio makeup set these two growth ETFs apart. Here's what that means for your investment strategy.
Via
The Motley Fool
Topics
ETFs
Stocks
CAPR Stock Slides After FDA Requests More Data For Genetic Disorder Therapy — What Does Retail Think?
↗
January 20, 2026
The FDA has formally requested the full HOPE-3 clinical study report (CSR) and supporting data, Capricor said on Tuesday.
Via
Stocktwits
IWY vs. IWO: IWY Goes Heavy on Big Tech, While IWO Focuses on Small Caps. Is Either One a Must-Own ETF?
↗
January 17, 2026
Explore how each ETF’s approach to diversification and sector focus shapes the balance between risk and opportunity for growth investors.
Via
The Motley Fool
Topics
ETFs
Why Did CRMD Stock Crash 28% Today?
↗
January 08, 2026
CorMedix announced that for 2026, it expects revenue between $300 million and $320 million, compared to $310 million it reported in the full year 2025, according to preliminary data.
Via
Stocktwits
Better Growth ETF: Vanguard's MGK vs. iShares' IWO
↗
January 01, 2026
Expense ratios, sector bets, and portfolio concentration set these two growth ETFs apart in ways that matter for different investor goals.
Via
The Motley Fool
Topics
ETFs
IWO Offers Broader Diversification but Slower Growth Than VOOG
↗
December 16, 2025
Explore how sector mix and company size shape the risk and diversification profiles of these two growth-focused ETFs.
Via
The Motley Fool
Topics
ETFs
Which Growth Stock ETF is Better: Vanguard's VONG or iShares' IWO?
↗
December 15, 2025
Explore how each ETF’s sector mix, risk profile, and cost structure could shape your growth investing strategy.
Via
The Motley Fool
Topics
ETFs
IWM and IWO Provide Small-Cap Diversification, But One Offers More Growth Potential for Investors
↗
December 14, 2025
Compare how sector focus, cost, and risk profiles set these two small-cap ETFs apart for different investor priorities.
Via
The Motley Fool
Topics
ETFs
VUG vs. IWO: Is Large-Cap Growth or Small-Cap Diversification a Better Choice for Investors?
↗
December 14, 2025
Two growth ETFs, two distinct strategies -- see how cost, sector mix, and risk profiles set these funds apart for investors.
Via
The Motley Fool
Topics
ETFs
Could Buying the iShares Russell 2000 Growth ETF (IWO) Today Set You Up for Life?
↗
November 24, 2025
It's a good option if you're looking to add small-cap stocks to your portfolio. But it's not your only good option.
Via
The Motley Fool
Topics
ETFs
Economy
Retirement
VONG vs. IWO: Does Large-Cap Growth or Small-Cap Diversification Pay Off More for Investors?
↗
November 20, 2025
VONG has a few clear advantages, but don't discount IWO's edge when it comes to diversification.
Via
The Motley Fool
Topics
ETFs
Why Did Tvardi Therapeutics Stock Plummet 87% Pre-Market Today?
↗
October 13, 2025
The company said that its investigational drug did not meet its goal in a study, and no statistically significant differences between placebo and treatment arms were observed after preliminary review...
Via
Stocktwits
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.